These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 34192548)

  • 1. Targeting p130Cas- and microtubule-dependent MYC regulation sensitizes pancreatic cancer to ERK MAPK inhibition.
    Waters AM; Khatib TO; Papke B; Goodwin CM; Hobbs GA; Diehl JN; Yang R; Edwards AC; Walsh KH; Sulahian R; McFarland JM; Kapner KS; Gilbert TSK; Stalnecker CA; Javaid S; Barkovskaya A; Grover KR; Hibshman PS; Blake DR; Schaefer A; Nowak KM; Klomp JE; Hayes TK; Kassner M; Tang N; Tanaseichuk O; Chen K; Zhou Y; Kalkat M; Herring LE; Graves LM; Penn LZ; Yin HH; Aguirre AJ; Hahn WC; Cox AD; Der CJ
    Cell Rep; 2021 Jun; 35(13):109291. PubMed ID: 34192548
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CHK1 protects oncogenic KRAS-expressing cells from DNA damage and is a target for pancreatic cancer treatment.
    Klomp JE; Lee YS; Goodwin CM; Papke B; Klomp JA; Waters AM; Stalnecker CA; DeLiberty JM; Drizyte-Miller K; Yang R; Diehl JN; Yin HH; Pierobon M; Baldelli E; Ryan MB; Li S; Peterson J; Smith AR; Neal JT; McCormick AK; Kuo CJ; Counter CM; Petricoin EF; Cox AD; Bryant KL; Der CJ
    Cell Rep; 2021 Nov; 37(9):110060. PubMed ID: 34852220
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Application of a MYC degradation screen identifies sensitivity to CDK9 inhibitors in KRAS-mutant pancreatic cancer.
    Blake DR; Vaseva AV; Hodge RG; Kline MP; Gilbert TSK; Tyagi V; Huang D; Whiten GC; Larson JE; Wang X; Pearce KH; Herring LE; Graves LM; Frye SV; Emanuele MJ; Cox AD; Der CJ
    Sci Signal; 2019 Jul; 12(590):. PubMed ID: 31311847
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Src family kinase oncogenic potential and pathways in prostate cancer as revealed by AZD0530.
    Chang YM; Bai L; Liu S; Yang JC; Kung HJ; Evans CP
    Oncogene; 2008 Oct; 27(49):6365-75. PubMed ID: 18679417
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-Term ERK Inhibition in KRAS-Mutant Pancreatic Cancer Is Associated with MYC Degradation and Senescence-like Growth Suppression.
    Hayes TK; Neel NF; Hu C; Gautam P; Chenard M; Long B; Aziz M; Kassner M; Bryant KL; Pierobon M; Marayati R; Kher S; George SD; Xu M; Wang-Gillam A; Samatar AA; Maitra A; Wennerberg K; Petricoin EF; Yin HH; Nelkin B; Cox AD; Yeh JJ; Der CJ
    Cancer Cell; 2016 Jan; 29(1):75-89. PubMed ID: 26725216
    [TBL] [Abstract][Full Text] [Related]  

  • 6. KRAS Suppression-Induced Degradation of MYC Is Antagonized by a MEK5-ERK5 Compensatory Mechanism.
    Vaseva AV; Blake DR; Gilbert TSK; Ng S; Hostetter G; Azam SH; Ozkan-Dagliyan I; Gautam P; Bryant KL; Pearce KH; Herring LE; Han H; Graves LM; Witkiewicz AK; Knudsen ES; Pecot CV; Rashid N; Houghton PJ; Wennerberg K; Cox AD; Der CJ
    Cancer Cell; 2018 Nov; 34(5):807-822.e7. PubMed ID: 30423298
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The tumor suppressor KLF11 mediates a novel mechanism in transforming growth factor beta-induced growth inhibition that is inactivated in pancreatic cancer.
    Buck A; Buchholz M; Wagner M; Adler G; Gress T; Ellenrieder V
    Mol Cancer Res; 2006 Nov; 4(11):861-72. PubMed ID: 17114344
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Concurrent Inhibition of IGF1R and ERK Increases Pancreatic Cancer Sensitivity to Autophagy Inhibitors.
    Stalnecker CA; Grover KR; Edwards AC; Coleman MF; Yang R; DeLiberty JM; Papke B; Goodwin CM; Pierobon M; Petricoin EF; Gautam P; Wennerberg K; Cox AD; Der CJ; Hursting SD; Bryant KL
    Cancer Res; 2022 Feb; 82(4):586-598. PubMed ID: 34921013
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tamoxifen treatment promotes phosphorylation of the adhesion molecules, p130Cas/BCAR1, FAK and Src, via an adhesion-dependent pathway.
    Cowell LN; Graham JD; Bouton AH; Clarke CL; O'Neill GM
    Oncogene; 2006 Dec; 25(58):7597-607. PubMed ID: 16799644
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Low-Dose Vertical Inhibition of the RAF-MEK-ERK Cascade Causes Apoptotic Death of KRAS Mutant Cancers.
    Ozkan-Dagliyan I; Diehl JN; George SD; Schaefer A; Papke B; Klotz-Noack K; Waters AM; Goodwin CM; Gautam P; Pierobon M; Peng S; Gilbert TSK; Lin KH; Dagliyan O; Wennerberg K; Petricoin EF; Tran NL; Bhagwat SV; Tiu RV; Peng SB; Herring LE; Graves LM; Sers C; Wood KC; Cox AD; Der CJ
    Cell Rep; 2020 Jun; 31(11):107764. PubMed ID: 32553168
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fisetin Enhances the Cytotoxicity of Gemcitabine by Down-regulating ERK-MYC in MiaPaca-2 Human Pancreatic Cancer Cells.
    Kim N; Kang MJ; Lee SH; Son JH; Lee JE; Paik WH; Ryu JK; Kim YT
    Anticancer Res; 2018 Jun; 38(6):3527-3533. PubMed ID: 29848706
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combination of ERK and autophagy inhibition as a treatment approach for pancreatic cancer.
    Bryant KL; Stalnecker CA; Zeitouni D; Klomp JE; Peng S; Tikunov AP; Gunda V; Pierobon M; Waters AM; George SD; Tomar G; Papke B; Hobbs GA; Yan L; Hayes TK; Diehl JN; Goode GD; Chaika NV; Wang Y; Zhang GF; Witkiewicz AK; Knudsen ES; Petricoin EF; Singh PK; Macdonald JM; Tran NL; Lyssiotis CA; Ying H; Kimmelman AC; Cox AD; Der CJ
    Nat Med; 2019 Apr; 25(4):628-640. PubMed ID: 30833752
    [TBL] [Abstract][Full Text] [Related]  

  • 13. U1 Adaptors Suppress the
    Tsang AT; Dudgeon C; Yi L; Yu X; Goraczniak R; Donohue K; Kogan S; Brenneman MA; Ho ES; Gunderson SI; Carpizo DR
    Mol Cancer Ther; 2017 Aug; 16(8):1445-1455. PubMed ID: 28377488
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nicotine promotes initiation and progression of KRAS-induced pancreatic cancer via Gata6-dependent dedifferentiation of acinar cells in mice.
    Hermann PC; Sancho P; Cañamero M; Martinelli P; Madriles F; Michl P; Gress T; de Pascual R; Gandia L; Guerra C; Barbacid M; Wagner M; Vieira CR; Aicher A; Real FX; Sainz B; Heeschen C
    Gastroenterology; 2014 Nov; 147(5):1119-33.e4. PubMed ID: 25127677
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting the yin and the yang: combined inhibition of the tyrosine kinase c-Src and the tyrosine phosphatase SHP-2 disrupts pancreatic cancer signaling and biology in vitro and tumor formation in vivo.
    Gomes EG; Connelly SF; Summy JM
    Pancreas; 2013 Jul; 42(5):795-806. PubMed ID: 23271399
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PIN1 Maintains Redox Balance via the c-Myc/NRF2 Axis to Counteract Kras-Induced Mitochondrial Respiratory Injury in Pancreatic Cancer Cells.
    Liang C; Shi S; Liu M; Qin Y; Meng Q; Hua J; Ji S; Zhang Y; Yang J; Xu J; Ni Q; Li M; Yu X
    Cancer Res; 2019 Jan; 79(1):133-145. PubMed ID: 30355620
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting ERK enhances the cytotoxic effect of the novel PI3K and mTOR dual inhibitor VS-5584 in preclinical models of pancreatic cancer.
    Ning C; Liang M; Liu S; Wang G; Edwards H; Xia Y; Polin L; Dyson G; Taub JW; Mohammad RM; Azmi AS; Zhao L; Ge Y
    Oncotarget; 2017 Jul; 8(27):44295-44311. PubMed ID: 28574828
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combination Therapies with CDK4/6 Inhibitors to Treat KRAS-Mutant Pancreatic Cancer.
    Goodwin CM; Waters AM; Klomp JE; Javaid S; Bryant KL; Stalnecker CA; Drizyte-Miller K; Papke B; Yang R; Amparo AM; Ozkan-Dagliyan I; Baldelli E; Calvert V; Pierobon M; Sorrentino JA; Beelen AP; Bublitz N; Lüthen M; Wood KC; Petricoin EF; Sers C; McRee AJ; Cox AD; Der CJ
    Cancer Res; 2023 Jan; 83(1):141-157. PubMed ID: 36346366
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CUDC-907 displays potent antitumor activity against human pancreatic adenocarcinoma in vitro and in vivo through inhibition of HDAC6 to downregulate c-Myc expression.
    Fu XH; Zhang X; Yang H; Xu XW; Hu ZL; Yan J; Zheng XL; Wei RR; Zhang ZQ; Tang SR; Geng MY; Huang X
    Acta Pharmacol Sin; 2019 May; 40(5):677-688. PubMed ID: 30224636
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An integrative pharmacogenomics analysis identifies therapeutic targets in KRAS-mutant lung cancer.
    Wang H; Lv Q; Xu Y; Cai Z; Zheng J; Cheng X; Dai Y; Jänne PA; Ambrogio C; Köhler J
    EBioMedicine; 2019 Nov; 49():106-117. PubMed ID: 31668570
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.